Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Sign up for Axios NW Arkansas
Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters
Alex Ritter, Jennifer Lippincott Schwartz and Gillian Griffiths, National Institutes of Health
Scientists have identified the genes in cancer cells that are required in order for cancer immunotherapies to work. If clinical studies validate the findings, it could eventually help to tailor more effective treatments for patients based on the genetic profiles of cancer tumors.
What they did: Researchers used CRISPR gene editing to knock out the function of each of a human melanoma cell's 19,000 genes — and then tested whether the modified cancer cells could be destroyed by immune cells. They found about 100 genes in the cancer cells that, when their function was lost, made cells resistant to immunotherapies. Some were previously implicated but others were unknown to have had a role.
How it works: Cancer immunotherapies leverage the body's own immune T cells to destroy tumors. They're used to treat late-stage melanoma, bladder, neck and other cancers — with varying success. Why some tumors are susceptible and others are not is a question of intense interest for doctors and scientists who want to see immunotherapies work in more patients.
Next steps: "If we can truly understand mechanisms of resistance to immunotherapy, we might be able to develop new therapeutics," NCI's Nicholas Restifo said in a press release. "In fact, in the future, this knowledge could speed the development of a new category of drugs that can circumvent these escape mechanisms of tumor cells and help patients experience complete responses."